Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

23 Apr, 2021

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management
Photo by Dimitry Anikin on Unsplash

– Jaguar Gene Therapy announced a $139m Series B funding co-led by Eli Lilly and Company and Deerfield Management.
– Also participating in the round were ARCH Venture Partners, Goldman Sachs, and Nolan Capital.
– The company is advancing AXV101, a gene therapy treatment for BBS1, a subset of Bardet-Biedl syndrome (BBS). A life-threatening neurometabolic condition, BBS causes progressive vision loss, severe obesity, learning disorders and kidney disease.
– The company is leveraging a proven management team with the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments for patients suffering from severe genetic diseases.
– Jaguar is led by former AveXis leadership.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: